Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
N. Holling (Bristol, United Kingdom), S. Patole (Bristol, United Kingdom), A. Medford (Bristol, United Kingdom), N. Maskell (Bristol, United Kingdom), A. Bibby (Bristol, United Kingdom). In patients with treatment-sensitive cancers, does systemic anti-cancer therapy increase the chance of malignant pleural effusion control?. 1141

Member's Comments

No comment yet.

Related content which might interest you: Systemic treatment of malignant pleural effusion Source: Annual Congress 2005 - What's new in the pleura Year: 2005 Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Pleural effusion in lung cancer and targeted therapy Source: Hands-on Course 2013 - Medical Thoracoscopy Year: 2013 Management of malignant pleural effusion in recurrent SCLC by intrapleural gene therapy Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Survival of lung adenocarcinoma patients with malignant pleural effusion Source: Eur Respir J 2013; 41: 1409-1418 Year: 2013 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Efficacy of EGFR-TKI for malignant pleural effusion in lung adenocarcinoma patients Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Outcomes of cytology positive malignant pleural effusions; do certain malignancies predispose patients to trapped lung? Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice? Year: 2019 Evaluation of concomitant pleural effusions in patients with lung cancers Source: Eur Respir J 2007; 30: Suppl. 51, 668s Year: 2007 Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009 Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 Clinical usefulness of the novel drug sensitivity test for malignancy using pleural effusion Source: Annual Congress 2006 - Lung cancer biology and chemosensitivity Year: 2006 Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer Source: Annual Congress 2005 - What's new in the pleura Year: 2005 Talc chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to breast cancer Source: Eur Respir J 2003; 22: Suppl. 45, 509s Year: 2003 Impact of sarcopenia in long-term symptoms in patients with malignant pleural effusion. Source: Virtual Congress 2021 – Accurate diagnosis and prediction of malignant pleural disease Year: 2021 An update on treatment of malignant pleural effusion with or without known primary bronchial adenocarcinoma Source: Annual Congress 2006 - Medical and surgical management of malignant pleuritis Year: 2006 How often is a single therapeutic aspiration sufficient to manage a malignant pleural effusion and does oncological treatment have an impact on this? Source: International Congress 2019 – Pleural disease: applying the evidence Year: 2019 Elevated circulating activin A levels in malignant pleural mesothelioma patients are related to cancer cachexia and poor response to platinum-based chemotherapy Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019